Safety and Efficacy of Forodesine for a Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified with Liver Failure

Author Details

Naruko Suzuki, Junji Hiraga, Yusuke Takagi, Michihiko Narita, Yoshitoyo Kagami

Journal Details

Published

Published: 21 December 2019 | Article Type :

Abstract

Malignant lymphoma patients complicated with liver dysfunction is known for its difficulty in treatment. Forodesine is a purine nucleoside phosphorylase inhibitor approved in Japan for the treatment of peripheral T-cell lymphoma (PTCL), and its administration in liver failure patients are unknown. We experienced a 72-year-old woman with recurrent PTCL, not otherwise specified (NOS), and severe liver dysfunction caused by nonalcoholic steatohepatitis treated with forodesine. She remained in stable disease for six months by continuing forodesine, and no remarkable adverse effects occurred. Forodesine may be considered for PTCL patients complicated with severe liver dysfunction.

Keywords: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), relapse, forodesine, liver failure.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © Author(s) retain the copyright of this article.

Statistics

304 Views

440 Downloads

Volume & Issue

Article Type

How to Cite

Citation:

Naruko Suzuki, Junji Hiraga, Yusuke Takagi, Michihiko Narita, Yoshitoyo Kagami. (2019-12-21). "Safety and Efficacy of Forodesine for a Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified with Liver Failure." *Volume 3*, 1, 9-12